靶向CD19治疗急性B淋巴细胞白血病的研究进展

Progress of CD19-targeted therapy for acute B-lymphoblastic leukemia

急性B淋巴细胞白血病(B-ALL)是急性淋巴细胞白血病最常见的类型,目前治疗以化疗为主,但具有严重的不良反应。CD19普遍在B系恶性肿瘤中高表达,并在B细胞信号转导、活化以及发育等过程起关键作用,成为B细胞恶性肿瘤治疗的有效靶点之一。目前开发了多种靶向CD19的疗法,包括抗体药物偶联物、单克隆抗体、双特异性抗体和嵌合抗原受体细胞疗法等。文章就近年靶向CD19治疗B-ALL的临床试验研究进展进行综述。

Acute B-lymphoblastic leukemia(B-ALL)is the most common type of acute lymphoblastic leukemia.Chemotherapy is the main treatment for most patients,but there are serious side effects.CD19 is generally highly expressed in B-lineage malignancies and plays a key role in B cell signal transduction,activation and development.Therefore,it has become one of the effective targets for treatment of B-cell malignancies.At present,a variety of therapies targeting CD19 have been developed,including antibody drug conjugates,monoclonal antibodies,bispecific antibodies and chimeric antigen receptors cell therapies.This paper reviews the clinical trial progress of CD19-targeted therapy for B-ALL.